Oppenheimer Sticks to Their Buy Rating for Nucana (NCNA)


Oppenheimer analyst Leland Gershell maintained a Buy rating on Nucana (NCNA) today and set a price target of $20.00. The company’s shares closed last Friday at $7.00.

According to TipRanks.com, Gershell is a 4-star analyst with an average return of 14.9% and a 47.7% success rate. Gershell covers the Healthcare sector, focusing on stocks such as Milestone Pharmaceuticals, BioMarin Pharmaceutical, and Corbus Pharmaceuticals.

Currently, the analyst consensus on Nucana is a Strong Buy with an average price target of $17.33.

See today’s analyst top recommended stocks >>

The company has a one-year high of $10.59 and a one-year low of $3.81. Currently, Nucana has an average volume of 431.5K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

NuCana Plc engages in the development of technology platform for the treatment of patients with cancer. Its Protide technology is consists of acelarin, NUC-3373, and NUC-7738. The company was founded by Hugh S. Griffith and Christopher B. Wood on January 28, 1997 and is headquartered in Edinburgh, the United Kingdom.

Read More on NCNA:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts